Search | TVST | ARVO Journals

Showing 1 – 20 of 26

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

Articles March 2022

Comparison of Visual Acuity Results Between ATS-HOTV and E-ETDRS Testing Methods in Children With Optic Pathway Gliomas

PDF

Robert A. Avery; Cammille Go; Michael J. Fisher; Grant T. Liu; Arielle Garcia; Meg Richter; Brendan McGeehan; Graham E. Quinn; Gui-Shuang Ying
TAGS: child, glioma, optics, visual acuity
Trans. Vis. Sci. Tech.. 2022; 11(3):10. doi: https://doi.org/10.1167/tvst.11.3.10

Special Issue October 2021

One-Year Follow-Up in a Phase 1/2a Clinical Trial of an Allogeneic RPE Cell Bioengineered Implant for Advanced Dry Age-Related Macular Degeneration

PDF

Amir H. Kashani; Jane S. Lebkowski; Firas M. Rahhal; Robert L. Avery; Hani Salehi-Had; Sanford Chen; Clement Chan; Neal Palejwala; April Ingram; Wei Dang; Chih-Min Lin; Debbie Mitra; Britney O. Pennington; Cassidy Hinman; Mohamed A. Faynus; Jeffrey K. Bailey; Sukriti Mohan; Narsing Rao; Lincoln V. Johnson; Dennis O. Clegg; David R. Hinton; Mark S. Humayun
TAGS: age-related macular degeneration, follow-up, implants, retinal pigment cell, surgical procedures, operative, postoperative care, therapeutic immunosuppression
Trans. Vis. Sci. Tech.. 2021; 10(10):13. doi: https://doi.org/10.1167/tvst.10.10.13

Includes: Supplemental Content

ARVO Annual Meeting Abstract July 2019

Identification of Photoreceptor Protein, Retinol Binding Protein 3 (RBP3), as a Protective Factor for Diabetic Retinopathy

Ward Fickweiler; Hisashi Yokomizo; Kyoungmin Park; Allen C Clermont; Yasutaka Maeda; Samantha M Paniagua; I-Hsien Wu; David Pober; Vanessa Bahnam; Robert L Avery; Timothy S Kern; Edward Feener; Lloyd P Aiello; Jennifer K Sun; George Liang King

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):6427. doi:

Letters to the Editor August 2018

Comments on Assays Used to Measure VEGF in the Presence of Anti-VEGF Therapeutics

PDF

Eric Wakshull; Robert Avery; Mauricio Maia
TAGS: anti-vascular endothelial growth factor therapy, therapeutics, vascular endothelial growth factor a
Invest. Ophthalmol. Vis. Sci.. 2018; 59(10):4106. doi: https://doi.org/10.1167/iovs.18-24792

ARVO Annual Meeting Abstract July 2018

Treat and Extend Versus Bi-monthly dosing with Aflibercept for the Treatment of Diabetic Macular Edema, One Year Outcomes (EVADE Study)

Jack M Giust; Alessandro Castellarin; Nathan Steinle; Dante Joseph Pieramici; Robert F. See; Robert L Avery; Gabriel M Gordon; Dilsher Dhoot

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):1957. doi:

ARVO Annual Meeting Abstract July 2018

Does Anti-VEGF Treatment for AMD Lower the Risk of Neovascularization in the Fellow Eye? A Meta-analysis

Robert L Avery; Gabriel M Gordon

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):1474. doi:

ARVO Annual Meeting Abstract June 2017

Cost Evaluation of Pneumatic Vitreolysis in Treatment for Vitreomacular Adhesion

Gabriel M Gordon; Robert L Avery

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1592. doi:

ARVO Annual Meeting Abstract June 2017

Incidence of New Choroidal Neovascularization in Fellow Eyes of Patients Treated with Intravitreal Aflibercept Injection or Ranibizumab in the VIEW studies

Robert L Avery

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):420. doi:

ARVO Annual Meeting Abstract September 2016

Comparison of Three Non-surgical Treatments for Vitreomacular Traction (VMT)

Nathan Steinle; Dilsher Dhoot; Dante Joseph Pieramici; Robert F See; Alessandro Castellarin; Steven Couvillion; Maan Nasir; Robert L Avery

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12) doi:

ARVO Annual Meeting Abstract September 2016

Eye Drop Adherence Following Retina Surgery

Daniel Glasser; Soratree Charoenthongtrakul; Hussein Wafapoor; Robert L Avery; Alexander M Eaton

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):4000. doi:

Articles August 2016

Volume Averaging of Spectral-Domain Optical Coherence Tomography Impacts Retinal Segmentation in Children

PDF

Carmelina Trimboli-Heidler; Kelly Vogt; Robert A. Avery
TAGS: child, spectral domain-optical coherence tomography, volume
Trans. Vis. Sci. Tech.. 2016; 5(4):12. doi: https://doi.org/10.1167/tvst.5.4.12

ARVO Annual Meeting Abstract June 2015

Systemic Safety of Monthly Anti-VEGF Injections for Diabetic Macular Edema (DME)

Robert L Avery; Gabriel M Gordon

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):1508. doi:

ARVO Annual Meeting Abstract June 2015

Intravitreal Perfluoropropane Gas (C3F8) Versus Ocriplasmin for Vitreomacular Traction (VMT)

Nathan Steinle; Dilsher Dhoot; Carlos Quezada; Ma'an A Nasir; Dante Joseph Pieramici; Robert See; Steve Couvillion; Alessandro Castellarin; Robert L Avery

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):3515. doi:

ARVO Annual Meeting Abstract June 2015

In Vivo and In vitro Force Testing of a New Guarded Injection Device

Alexander M Eaton; Gabriel M Gordon; Dave Booth; Hussein Wafapoor; Robert L Avery; Dyson Hickingbotham

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):393. doi:

Genetics April 2015

Identification of a Novel Mucin Gene HCG22 Associated With Steroid-Induced Ocular Hypertension

PDF

Shinwu Jeong; Nitin Patel; Christopher K. Edlund; Jaana Hartiala; Dennis J. Hazelett; Tatsuo Itakura; Pei-Chang Wu; Robert L. Avery; Janet L. Davis; Harry W. Flynn; Geeta Lalwani; Carmen A. Puliafito; Hussein Wafapoor; Minako Hijikata; Naoto Keicho; Xiaoyi Gao; Pablo Argüeso; Hooman Allayee; Gerhard A. Coetzee; Mathew T. Pletcher; David V. Conti; Stephen G. Schwartz; Alexander M. Eaton; M. Elizabeth Fini
TAGS: cohort studies, genes, intraocular pressure, mucins, ocular hypertension, single nucleotide polymorphism, steroids, dna, proteins, genome-wide association study
Invest. Ophthalmol. Vis. Sci.. 2015; 56(4):2737-2748. doi: https://doi.org/10.1167/iovs.14-14803

Includes: Supplemental Content

ARVO Annual Meeting Abstract April 2014

Outer Band Reflectivity Changes on SD-OCT Following Intravitreal Ocriplasmin for Vitreomacular Traction (VMT) and macular holes (MH)

Nathan C Steinle; Carlos Quezada; Ma Nasir; Dante Joseph Pieramici; Alessandro Castellarin; Robert F See; Stephen Couvillion; Dilsher Dhoot; Melvin Rabena; Robert L Avery; California Retina Consultants

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):296. doi:

ARVO Annual Meeting Abstract April 2014

Systemic Pharmacokinetics Following Intravitreal Injections of Ranibizumab, Bevacizumab or Aflibercept in Patients with DME

Robert L Avery; Alessandro Castellarin; Nathan Steinle; Dilsher Dhoot; Dante Joseph Pieramici; Robert F See; Stephen Couvillion; Ma Nasir; Kha Le; Jennifer Visich

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):586. doi:

Eye Movements, Strabismus, Amblyopia and Neuro-ophthalmology March 2014

Ganglion Cell Layer–Inner Plexiform Layer Thickness and Vision Loss in Young Children With Optic Pathway Gliomas

PDF

Sherry Gu; Natalie Glaug; Avital Cnaan; Roger J. Packer; Robert A. Avery
TAGS: blindness, child, eye, ganglia, glioma
Invest. Ophthalmol. Vis. Sci.. 2014; 55(3):1402-1408. doi: https://doi.org/10.1167/iovs.13-13119

ARVO Annual Meeting Abstract June 2013

Meta-analysis examining the systemic safety profile of intravitreal ranibizumab injections in AMD, RVO and DME

Robert Avery; Steven Francom; Phillip Lai; Chad Melson; Sung Cha; Lisa Tuomi

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):1535. doi:

ARVO Annual Meeting Abstract June 2013

Ranibizumab 0.5mg and 2.0mg to Treat Diabetic Macular Edema in Patients With Poor Response to Bevacizumab

Dante Pieramici; Ma'an Nasir; Alessandro Castellarin; Robert See; Steve Couvillion; Michael Bennett; Melvin Rabena; Jack Giust; Lisha Wan; Robert Avery

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):2413. doi:

1 2

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Comparison of Visual Acuity Results Between ATS-HOTV and E-ETDRS Testing Methods in Children With Optic Pathway Gliomas

One-Year Follow-Up in a Phase 1/2a Clinical Trial of an Allogeneic RPE Cell Bioengineered Implant for Advanced Dry Age-Related Macular Degeneration

Identification of Photoreceptor Protein, Retinol Binding Protein 3 (RBP3), as a Protective Factor for Diabetic Retinopathy

Comments on Assays Used to Measure VEGF in the Presence of Anti-VEGF Therapeutics

Treat and Extend Versus Bi-monthly dosing with Aflibercept for the Treatment of Diabetic Macular Edema, One Year Outcomes (EVADE Study)

Does Anti-VEGF Treatment for AMD Lower the Risk of Neovascularization in the Fellow Eye? A Meta-analysis

Cost Evaluation of Pneumatic Vitreolysis in Treatment for Vitreomacular Adhesion

Incidence of New Choroidal Neovascularization in Fellow Eyes of Patients Treated with Intravitreal Aflibercept Injection or Ranibizumab in the VIEW studies

Comparison of Three Non-surgical Treatments for Vitreomacular Traction (VMT)

Eye Drop Adherence Following Retina Surgery

Volume Averaging of Spectral-Domain Optical Coherence Tomography Impacts Retinal Segmentation in Children

Systemic Safety of Monthly Anti-VEGF Injections for Diabetic Macular Edema (DME)

Intravitreal Perfluoropropane Gas (C3F8) Versus Ocriplasmin for Vitreomacular Traction (VMT)

In Vivo and In vitro Force Testing of a New Guarded Injection Device

Identification of a Novel Mucin Gene HCG22 Associated With Steroid-Induced Ocular Hypertension

Outer Band Reflectivity Changes on SD-OCT Following Intravitreal Ocriplasmin for Vitreomacular Traction (VMT) and macular holes (MH)

Systemic Pharmacokinetics Following Intravitreal Injections of Ranibizumab, Bevacizumab or Aflibercept in Patients with DME

Ganglion Cell Layer–Inner Plexiform Layer Thickness and Vision Loss in Young Children With Optic Pathway Gliomas

Meta-analysis examining the systemic safety profile of intravitreal ranibizumab injections in AMD, RVO and DME

Ranibizumab 0.5mg and 2.0mg to Treat Diabetic Macular Edema in Patients With Poor Response to Bevacizumab

To View More...

You must be signed into an individual account to use this feature.